NuCana (NASDAQ:NCNA – Get Free Report) is expected to post its results before the market opens on Thursday, May 14th. Analysts expect NuCana to post earnings of ($2.6440) per share for the quarter.
NuCana Stock Down 6.6%
Shares of NASDAQ:NCNA opened at $1.97 on Tuesday. NuCana has a 52 week low of $1.33 and a 52 week high of $40.00. The company has a market cap of $8.20 million, a P/E ratio of -0.02 and a beta of 2.17. The company has a 50-day moving average price of $1.94 and a 200 day moving average price of $2.84.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.
About NuCana
NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.
At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.
Further Reading
- Five stocks we like better than NuCana
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.
